The aim of the Lupus Nexus is to transform lupus research and drug development through unprecedented information exchange capabilities. The platform will provide a collaborative solution that is inclusive of diverse patient populations disproportionally affected by lupus.
Posts
The funds, coupled with earlier Series A financing, provide the Indiana-based company with about $150 million in total funding that will support its clinical asset and other developmental programs, according to CEO Kent Hawryluk.
The early-stage study, which is being sponsored by BioNTech, aims to evaluate the combination shot’s safety, tolerability and immunogenicity, or the ability to generate immune response.